Related Experiment Video
Updated: May 29, 2026
08:47
Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
Published on: December 16, 2022
[Treating congestive heart failure with cardiac contractility modulation (CCM) : possibilities and study overview]
1Abt. Kardiologie, Asklepios Klinik St. Georg, Hamburg, Deutschland. t.toennis@asklepios.com
Herz
|September 14, 2011
Summary
Cardiac contractility modulation (CCM) therapy improves exercise capacity and quality of life in systolic heart failure patients. This device therapy modulates calcium cycling to enhance myocardial contractility.
Area of Science:
- Cardiology
- Biomedical Engineering
- Heart Failure Management
Background:
- Systolic heart failure significantly impacts patient quality of life and exercise tolerance.
- Current therapeutic options may not be sufficient for all symptomatic patients.
- Device-based therapies are emerging as a potential treatment modality.
Purpose of the Study:
- To describe Cardiac Contractility Modulation (CCM) therapy.
- To outline the mechanism of action for CCM.
- To define patient selection criteria and contraindications for CCM therapy.
Main Methods:
- CCM therapy involves applying non-excitatory electrical signals during the absolute refractory period.
- These signals modulate myocardial calcium cycling to enhance contractility.
- The therapy's effects on peak VO(2), quality of life, and exercise tolerance are evaluated.
Main Results:
- CCM therapy has demonstrated improvements in peak VO(2), quality of life, and exercise tolerance.
- It can be used as an adjunct to implantable cardioverter defibrillators (ICDs).
- Specific criteria for patient selection include LVEF ≤35% and NYHA class II-III.
Conclusions:
- CCM therapy is a viable option for select symptomatic systolic heart failure patients.
- Contraindications include atrial fibrillation, high-grade arrhythmias, and significant AV block.
- Patients with left bundle branch block may require prior biventricular ICD implantation.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.